Related references
Note: Only part of the references are listed.Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Daniel P. Petrylak et al.
PROSTATE (2020)
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
Shankar Siva et al.
NATURE REVIEWS UROLOGY (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Is there a role for repeating PSMA PET/CT after a negative scan in biochemical recurrent prostate cancer?
Georges Mjaess et al.
ACTA ONCOLOGICA (2020)
Potential of Radiolabeled PSMA PET/CT or PET/MRI Diagnostic Procedures in Gliomas/Glioblastomas
Francesco Bertagna et al.
CURRENT RADIOPHARMACEUTICALS (2020)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler et al.
JAMA ONCOLOGY (2019)
PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
Hans-Juergen Wester et al.
SEMINARS IN NUCLEAR MEDICINE (2019)
The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma
Sheliyan Raveenthiran et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer
Samantha Koschel et al.
CURRENT OPINION IN UROLOGY (2019)
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Chiara Pozzessere et al.
CURRENT UROLOGY REPORTS (2019)
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer
Daniel P. Petrylak et al.
PROSTATE (2019)
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
Nicholas M. Donin et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Advances in prostate-specific membrane antigen PET of prostate cancer
Kirsten Bouchelouche et al.
CURRENT OPINION IN ONCOLOGY (2018)
Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis
Sangwon Han et al.
EUROPEAN UROLOGY (2018)
Phase I dose-escalation study of Ac-225-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
Scott T. Tagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid
Birthe Heitkötter et al.
Oncotarget (2018)
PSMA Theranostics: Current Status and Future Directions
Kambiz Rahbar et al.
MOLECULAR IMAGING (2018)
A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen
Saima Nawaz et al.
NUCLEAR MEDICINE COMMUNICATIONS (2017)
Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach
Simone Albisinni et al.
BJU INTERNATIONAL (2017)
New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
Uwe Haberkorn et al.
CLINICAL CANCER RESEARCH (2016)
Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine
Kirsten Bouchelouche et al.
CURRENT OPINION IN ONCOLOGY (2016)
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer
Matthew I. Milowsky et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
Neeta Pandit-Taskar et al.
EJNMMI RESEARCH (2015)
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Neeta Pandit-Taskar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
A Prospective Pilot Study of 89Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
Joseph R. Osborne et al.
JOURNAL OF UROLOGY (2014)
Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2013)
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
John A. Barrett et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
Matthew D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms
Angelo Baccala et al.
UROLOGY (2007)
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Sven Perner et al.
HUMAN PATHOLOGY (2007)
Expression of prostate-specific membrane antigen in normal and malignant human tissues
Y Kinoshita et al.
WORLD JOURNAL OF SURGERY (2006)
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
MJ Morris et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
NH Bander et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
MI Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
